Skip to Main Content
Table 1

Baseline clinical characteristics of the study subjects (n = 26)

CharacteristicIntervention (n = 15)Control (n = 11)P                  a
Age    
 Median (range) 61 (51–71) 61 (53–70)  
 Mean ± SEb 62.3 ± 1.9 62.0 ± 1.8 0.92 
Race    
 African American  
 Caucasian American 13 0.62 
Baseline clinical stagec    
 T1C 10  
 T2A  
 T2B 0.13a 
Baseline Gleason score    
 ≤6 11  
 >6 0.23 
Baseline plasma PSA (ng/ml) 6.89 ± 0.81b 6.74 ± 0.88 0.89 
CharacteristicIntervention (n = 15)Control (n = 11)P                  a
Age    
 Median (range) 61 (51–71) 61 (53–70)  
 Mean ± SEb 62.3 ± 1.9 62.0 ± 1.8 0.92 
Race    
 African American  
 Caucasian American 13 0.62 
Baseline clinical stagec    
 T1C 10  
 T2A  
 T2B 0.13a 
Baseline Gleason score    
 ≤6 11  
 >6 0.23 
Baseline plasma PSA (ng/ml) 6.89 ± 0.81b 6.74 ± 0.88 0.89 
a

P is for comparing the distribution of T1versus T2 in the two groups.

b

Mean + SE.

c

American Urologic Association (AUA) Staging System: T1C, tumor on needle biopsy of nonpalpable mass; T2A, tumor involving one lobe; T2B, tumor involving both lobes.

Close Modal

or Create an Account

Close Modal
Close Modal